Hemab Therapeutics' IPO

Q: When does the lock-up end?

Hemab Therapeutics' IPO lock-up ends Oct 27, 2026. Its final prospectus says: “.”

Listed May 1, 2026 at $18 on Nasdaq as COAG.

Offer price

$18

Market cap

$795M

16,750,000

Today 100% above its $18 offer price; its first day closed +88.9%.

Breakaway does the work for you: insider and Congress trades, the chart, and the financials, in one score.

See COAG ranked, live

See it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

From its final prospectus (424B4) on SEC EDGAR, filed May 1, 2026.

What does Hemab Therapeutics do?

“We are a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience.”

From its final prospectus (424B4), filed May 1, 2026

Hemab Therapeutics' facts, each with its source
Fact	Hemab Therapeutics
Incorporated	Delaware, 2026From its final prospectus (424B4) of May 1, 2026
Headquarters	Cambridge, MassachusettsFrom its final prospectus (424B4) of May 1, 2026
Employees	72 full-time, as of March 31, 2026From its final prospectus (424B4) of May 1, 2026
Website	hemab.comFrom its final prospectus (424B4) of May 1, 2026

What is the offering?

Each figure names the filing it is from and that filing's date. The market cap is Breakaway's arithmetic from the prospectus's share count.

Hemab Therapeutics' facts, each with its source
Fact	Hemab Therapeutics
Shares offered	16,750,000From the final prospectus (424B4) filed May 1, 2026
Offer price	$18 a shareFrom the final prospectus (424B4) filed May 1, 2026
Raised at that price	$302 millionFrom the final prospectus (424B4) filed May 1, 2026
Underwriters' discount	$21.1 millionFrom the final prospectus (424B4) filed May 1, 2026
Net proceeds the company expects	About $275 millionFrom the final prospectus (424B4) filed May 1, 2026
Underwriters' option	2,512,500 more sharesFrom the final prospectus (424B4) filed May 1, 2026
Underwriters	Goldman Sachs, Jefferies, Evercore ISI, and WedbushFrom the final prospectus (424B4) filed May 1, 2026, as its cover names them
Exchange	Nasdaq Global Select Market, as COAGFrom the final prospectus (424B4) filed May 1, 2026
Shares outstanding after	44,192,910From the final prospectus (424B4) filed May 1, 2026
Market cap at the offer price	$795 millionBreakaway's arithmetic from the prospectus's share count

What the filing says about its money

Hemab Therapeutics' facts, each with its source
Fact	Hemab Therapeutics
Revenue	None from product sales yetFrom its final prospectus (424B4) of May 1, 2026: it has not generated any revenue from product sales
Net loss	$63.9 million, year to December 31, 2025From its final prospectus (424B4) of May 1, 2026, its summary financial data
Cash	$186 million, as of December 31, 2025From its final prospectus (424B4) of May 1, 2026: cash, cash equivalents and marketable securities

What risks does Hemab Therapeutics name first?

“We have incurred significant losses since our inception and have no products approved for sale.”
“We have never generated revenue from product sales and may never achieve or maintain profitability.”
“We are heavily dependent on the success of sutacimig and HMB-002, which are our only clinical-stage product candidates.”

The first three of the risks its prospectus summary lists, in the company's words. The rest, and each in full, are in the filing. Read the filing.

Every date of Hemab Therapeutics' IPO

Hemab Therapeutics' IPO dates, each with its source
What	Day	Source
Registration filedForm S-1, SEC EDGAR	Apr 10, 2026	Form S-1, SEC EDGAR
Exchange registration filedexchange registration (Form 8-A), SEC EDGAR	Apr 27, 2026	exchange registration (Form 8-A), SEC EDGAR
Declared effective by the SECSEC notice of effectiveness, SEC EDGAR	Apr 30, 2026	SEC notice of effectiveness, SEC EDGAR
Pricedfinal prospectus (424B4), filed May 1, SEC EDGAR	Apr 30, 2026	final prospectus (424B4), filed May 1, SEC EDGAR
First tradeMassive's IPO calendar	May 1, 2026	Massive's IPO calendar
Lock-up endsfinal prospectus, SEC EDGAR: “”	Oct 27, 2026	final prospectus, SEC EDGAR: “”

How did its first days trade?

From its daily bars, each close against its $18 offer price.

Hemab Therapeutics' first sessions
Day	Open	Close	From the offer
May 1	$27	$34	+88.9%
May 4	$30.87	$25.34	+40.8%
May 5	$23.81	$25	+38.9%
May 6	$25.25	$25.01	+38.9%
May 7	$24.96	$25.74	+43.0%

What is Hemab Therapeutics' Quality Score?

Below Average

123 trading days so far; 3 of the 14 checks wait for more history.

COAG's page, with every reason behind its score

Tested. Our top-⁠scored stocks returned 2.2x the average stock over the next month. How we tested it

The other IPOs expected

The other IPOs expected or in registration
Company	Price	Market cap	Expected
OPAYNYSE: OPAY · No day yet	$19 to $21	Not yet	No day yetexchange registration Oct 26
Georgia BankingNasdaq: GBC · No day yet	Direct	Not yet	No day yetexchange registration Oct 21
Aspen NeuroscienceNasdaq: ASPE · No day yet	$15 to $17About $465M	$465Mat the midpoint	No day yetterms set Oct 26
Bambusa TherapeuticsNasdaq: BBTX · No day yet	$15 to $17About $796M	$796Mat the midpoint	No day yetterms set Oct 26
BitariNasdaq: BIAI · No day yet	$7About $302M	$302Mat the midpoint	No day yetterms set Oct 26
LIS TechnologiesNasdaq · No day yet	$5 to $7	Not yet	No day yetterms set Oct 26

Hemab Therapeutics IPO questions

When is Hemab Therapeutics' IPO?

Listed May 1, 2026 at $18 on Nasdaq as COAG.

What is Hemab Therapeutics' IPO price?

Hemab Therapeutics' IPO priced at $18 a share, per its final prospectus of May 1, 2026.

How many shares is Hemab Therapeutics selling?

16,750,000 shares, and the underwriters may buy 2,512,500 more, per its final prospectus (424B4).

Who are the underwriters?

Goldman Sachs, Jefferies, Evercore ISI, and Wedbush, as the prospectus's cover names them.

When does the lock-up end?

Hemab Therapeutics' IPO lock-⁠up ends Oct 27, 2026. Its final prospectus says: “.”

Does Breakaway rate Hemab Therapeutics?

Hemab Therapeutics has a Quality Score of 3 today. The score counts the 14 chart checks and the company's filings; a check that needs more history than a new stock has waits for it.

Can Breakaway say where Hemab Therapeutics' price will go?

No. Breakaway does not say where a price will go. Every figure here is from the company's SEC filings, linked on each line.

Where every figure comes from.

Each company's SEC filings on EDGAR, read twice a day: its registration (Form S-1 or F-1), the amendment that sets its price range, and its final prospectus (424B4). The shares, the price, the underwriters, the lock-up, and the company's words are the filing's, linked on each line.
The expected day is Massive's IPO calendar's, the first trade the market data's, and the moves each stock's daily closes against its offer price.
The market cap is Breakaway's arithmetic: the shares the prospectus says will be outstanding after the offering, times the midpoint of the range or the offer price.
The Quality Score is Breakaway's, from a stock's second trading day; for its first 21 sessions it is marked New listing, and each check that needs more history waits for it.
Blank-check companies (SPACs) and unit offerings are left out and counted; a direct listing and a US listing of a company listed abroad are in and marked.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

Every new listing, ranked live, free. No account.

See all 16 new listings ranked

See it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

Every IPO expected and listed, and May 2026's listings.